統合失調症：7市場の医薬品予測と市場分析 - 更新版

世界の統合失調症の主要7市場（米国、フランス、ドイツ、イタリア、スペイン、英国、日本）は、予測期間（2021年～2031年）に安定した成長を示す見込みです。この成長の主な促進要因は、その他の抗精神病薬との併用を目的とした5つの補助療法です。これらには、Neurocrine BiosciencesのIngrezza（valbenazine）とNBI-1117568、Bristol Myers SquibbのCobenfy（塩化トロスピウム + キサノメリン）、Boehringer IngelheimのIclepertin/BI-425809などが含まれます。上市済みの治療薬の大半はジェネリック化されていますが、Abilify MaintenaやAristadaなどの持続性注射剤（LAI）非定型抗精神病薬の特許切れが市場成長を抑制すると予測されます。

当レポートでは、統合失調症の主要7市場について調査し、統合失調症の概要、統合失調症治療市場の収益と予測、パイプラインの分析、現在と将来の競合の分析などを提供しています。

目次

第1章 統合失調症：エグゼクティブサマリー - 2024年11月更新、11月22日までの出来事に基づく

• 統合失調症の市場規模は170億米ドルに達する見込み
• 主要企業は競争力を維持するのに苦労すると見られる
• 統合失調症管理の見通しは前進している一方、患者転帰を改善する機会はまだ残っている
• 補助療法の参入により統合失調症市場が形成される
• 医師の考え

第2章 イントロダクション - 2024年11月更新

• カタリスト
• 関連レポート
• 今後のレポート

第3章 疾患の概要

• 病因と病態生理学
• 分類または段階分けのシステム

第4章 疫学

• 疾患の背景
• 危険因子と合併症
• 世界の過去の動向
• 主要7市場の予測手法
  • 使用された情報源
  • 予測の前提条件と手法
  • 予測の前提条件と手法：12ヶ月間の統合失調症の総患者数
• 統合失調症の疫学予測（2021年～2031年）
  • 12ヶ月間の統合失調症の総患者数
  • 12ヶ月間の統合失調症と診断された患者数
  • 12ヶ月間の統合失調症と診断された患者数：年齢別
  • 12ヶ月間に統合失調症と診断された患者数：性別
• 議論
  • 疫学予測の考察
  • COVID-19の影響
  • 分析の限界
  • 分析の強み

第5章 疾病管理 - 2024年11月更新、11月22日までの出来事に基づく

• 診断の概要
• 治療の概要
• 統合失調症の非薬物療法

第6章 競合の評価 - 2024年11月更新、11月22日までの出来事に基づく

• 概要

第7章 アンメットニーズと機会の評価 - 2024年11月更新、11月22日までの出来事に基づく

• 概要
• 統合失調症に伴う認知障害を標的とした治療法の開発
• 陰性症状を標的とした治療法の開発
• 治療抵抗性患者に対する治療法の開発
• 患者の理解と治療アドヒアランスの向上

第8章 R&D戦略 - 2024年11月更新、11月22日までの出来事に基づく

• 概要
  • 再処方と革新的なドラッグデリバリーシステム
  • 新しいMOA
  • 補助療法の開発
  • デジタル治療
• 臨床試験の設計
  • 臨床エンドポイント
  • 患者募集

第9章 パイプラインの評価 - 2024年11月更新、11月22日までの出来事に基づく

• 概要
• 臨床開発中の有望な医薬品

第10章 パイプラインの評価の分析 - 2024年11月更新、11月22日までの出来事に基づく

• 概要
• 競合の評価

第11章 現在と将来の参入企業 - 2024年11月更新、11月22日までの出来事に基づく

• 概要
• 取引の動向

第12章 市場見通し - 2024年11月更新、11月22日までの出来事に基づく

• 世界市場
  • 予測
  • 促進要因と障壁 - 世界的な問題
• 米国
  • 予測
  • 主な出来事
  • 促進要因と障壁
• 5EU
  • 予測
  • 主な出来事
  • 促進要因と障壁
• 日本
  • 予測
  • 主な出来事
  • 促進要因と障壁

第13章 付録

List of Tables

• Table 1: Schizophrenia: Key metrics in the 7MM
• Table 2: Risk factors and comorbid conditions associated with schizophrenia
• Table 3: Treatment Guidelines for Schizophrenia
• Table 4: Schizophrenia market - global drivers and barriers, 2021-31
• Table 5: Key events impacting sales for schizophrenia in the US, 2021-31
• Table 6: Schizophrenia Market - Drivers and Barriers in the US, 2021-31
• Table 7: Key events impacting sales for schizophrenia in the 5EU, 2021-31
• Table 8: Schizophrenia market - drivers and barriers in the 5EU, 2021-31
• Table 9: Key Events Impacting Sales for Schizophrenia in Japan, 2021-31
• Table 10: Schizophrenia Market - Drivers and Barriers in Japan, 2021-31
• Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

• Figure 1: Global sales forecast by country for schizophrenia in 2021 and 2031
• Figure 2: Analysis of the company portfolio gap in schizophrenia during the forecast period
• Figure 3: Competitive assessment of oral pipeline products that GlobalData expects to be licensed for the treatment of schizophrenia during the forecast period
• Figure 4: Competitive assessment of pipeline atypical antipsychotic reformulations benchmarked against the SOC, Invega Sustenna
• Figure 5: 7MM, 12-month total prevalence (%) of schizophrenia, both sexes, ages >=13 years, 2021
• Figure 6: 7MM, 12-month diagnosed prevalence (%) of schizophrenia, men and women, ages >=13 years, 2021
• Figure 7: 7MM, sources used to forecast the 12-month total prevalent cases of schizophrenia
• Figure 8: 7MM, sources used and not used to forecast the 12-month diagnosed prevalent cases of schizophrenia
• Figure 9: 7MM, 12-month total prevalent cases of schizophrenia, N, both sexes, ages >=13 years, 2021
• Figure 10: 7MM, 12-month diagnosed prevalent cases of schizophrenia, N, both sexes, ages >=13 years, 2021
• Figure 11: 7MM, 12-month diagnosed prevalent cases of schizophrenia by age, N, both sexes, 2021
• Figure 12: 7MM, 12-month diagnosed prevalent cases of schizophrenia by sex, N, ages >=13 years, 2021
• Figure 13: Unmet needs and opportunities in schizophrenia
• Figure 14: Overview of the development pipeline in schizophrenia
• Figure 15: Key late-stage trials for the promising pipeline agents that GlobalData expects to be launched for schizophrenia in the 7MM during the forecast period
• Figure 16: Competitive assessment of oral pipeline drugs benchmarked against the SOC, Abilify
• Figure 17: Competitive assessment of pipeline atypical antipsychotic reformulations benchmarked against the SOC, Invega Sustenna
• Figure 18: Analysis of the company portfolio gap in schizophrenia during the forecast period
• Figure 19: Global (7MM) sales forecast by country for schizophrenia in 2021 and 2031
• Figure 20: Sales forecast by class for schizophrenia in the 7MM in 2021 and 2031
• Figure 21: Sales forecast by class for schizophrenia in the US in 2021 and 2031
• Figure 22: Sales forecast by class for schizophrenia in the 5EU in 2021 and 2031
• Figure 23: Sales forecast by class for schizophrenia in Japan in 2021 and 2031

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the schizophrenia market through 2031.

GlobalData forecasts that the global schizophrenia marketplace-which, for the purposes of this report, comprises seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan)-to experience steady growth during the forecast period. This growth will be driven primarily by the launch of five adjunctive therapies that are designed to be used in combination with the other marketed antipsychotics. These include Neurocrine Biosciences' Ingrezza (valbenazine) and NBI-1117568, Bristol Myers Squibb's Cobenfy (trospium chloride + xanomeline), and Boehringer Ingelheim's Iclepertin/BI-425809. Although the majority of the therapies that are already in the market are genericized, patent expiries of long-acting injectable (LAI) atypical antipsychotics such as Abilify Maintena and Aristada are expected to curtail market growth.

This model covers the market forecast for schizophrenia marketed therapies and late-stage pipeline candidates. The base year of this model is 2021 and the forecast period is 2021-31.

Scope

• Overview of Schizophrenia, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized schizophrenia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the schizophrenia therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for schizophrenia treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global schizophrenia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM schizophrenia therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM schizophrenia therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

• About GlobalData

1 Schizophrenia: Executive Summary - Updated November 2024, Based on Events up to November 22

• 1.1 The schizophrenia market will grow to $17.0 billion.
• 1.2 Key players will struggle to maintain their competitive position.
• 1.3 While outlook for schizophrenia management made headway, opportunities remain to improve patient outcomes.
• 1.4 The entry of adjunctive therapies will shape the schizophrenia market.
• 1.5 What do physicians think?

2 Introduction - Updated November 2024

• 2.1 Catalyst
• 2.2 Related Reports
• 2.3 Upcoming Reports

3 Disease Overview

• 3.1 Etiology and Pathophysiology
  • 3.1.1 Etiology
  • 3.1.2 Pathophysiology
• 3.2 Classification or Staging Systems

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities.
• 4.3 Global and historical trends
• 4.4 7MM forecast methodology.
  • 4.4.1 Sources used.
  • 4.4.2 Forecast assumptions and methods.
  • 4.4.3 Forecast assumptions and methods: 12-month total prevalent cases of schizophrenia.
• 4.5 Epidemiological Forecast for Schizophrenia (2021-31)
  • 4.5.1 12-Month total prevalent cases of schizophrenia
  • 4.5.2 12-Month diagnosed prevalent cases of schizophrenia
  • 4.5.3 Age-specific 12-month diagnosed prevalent cases of schizophrenia.
  • 4.5.4 Sex-specific 12-month diagnosed prevalent cases of schizophrenia.
• 4.6 Discussion
  • 4.6.1 Epidemiological forecast insight
  • 4.6.2 COVID-19 Impact
  • 4.6.3 Limitations of Analysis
  • 4.6.4 Strengths of Analysis

5 Disease Management - Updated November 2024, Based on Events up to November 22

• 5.1 Diagnosis overview
• 5.2 Treatment overview
• 5.3 Non-pharmacological management of schizophrenia

6 Competitive Assessment - Updated November 2024, Based on Events up to November 22

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment - Updated November 2024, Based on Events up to November 22

• 7.1 Overview
• 7.2 Development of therapies to target cognitive impairment associated with schizophrenia
• 7.3 Development of therapies to target negative symptoms.
• 7.4 Development of therapies for treatment-resistant patients
• 7.5 Improved patient insight and adherence to treatment

8 R&D Strategies - Updated November 2024, Based on Events up to November 22

• 8.1 Overview
  • 8.1.1 Reformulations and innovative drug delivery systems
  • 8.1.2 Novel MOAs
  • 8.1.3 Development of adjunctive therapies
  • 8.1.4 Digital therapeutics
• 8.2 Clinical trial design
  • 8.2.1 Clinical endpoints
  • 8.2.2 Patient Recruitment

9 Pipeline Assessment - Updated November 2024, Based on Events up to November 22

• 9.1 Overview
• 9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis - Updated November 2024, Based on Events up to November 22

• 10.1 Overview
• 10.2 Competitive Assessment

11 Current and Future Players - Updated November 2024, Based on Events up to November 22

• 11.1 Overview
• 11.2 Deal-making trends

12 Market Outlook - Updated November 2024, Based on Events up to November 22

• 12.1 Global Markets
  • 12.1.1 Forecasts
  • 12.1.2 Drivers and barriers - global issues
• 12.2 US
  • 12.2.1 Forecast
  • 12.2.2 Key events
  • 12.2.3 Drivers and barriers
• 12.3 5EU
  • 12.3.1 Forecast
  • 12.3.2 Key events
  • 12.3.3 Drivers and barriers
• 12.4 Japan
  • 12.4.1 Forecast
  • 12.4.2 Key events
  • 12.4.3 Drivers and barriers

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
  • 13.3.1 Forecasting Methodology
• 13.4 Primary Research - KOLs Interviewed for This Report
  • 13.4.1 KOLs and Payers
• 13.5 Primary Research - Prescriber Survey
• 13.6 About the Authors
  • 13.6.1 Analyst
  • 13.6.2 Therapy Area Director
  • 13.6.3 Epidemiologist
  • 13.6.4 Managing Epidemiologists
  • 13.6.5 Vice President of Disease Analysis and Epidemiology
  • 13.6.6 Global Head of Pharma Research, Analysis and Competitive Intelligence
• Contact Us